We are live on
!
Find out more
Aberdeen Group Portfolio holdings
AUM
$61.9B
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+5.07%
1 Year Est. Return
+29.81%
3 Year Est. Return
+93.17%
5 Year Est. Return
+119.65%
10 Year Est. Return
–
AUM
$64.6B
AUM Growth
+$1.37B
(+2.2%)
Cap. Flow
-$686M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
38.17%
Holding
995
New
43
Increased
362
Reduced
491
Closed
59
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nu Holdings
NU
|
+$36.3M |
| 2 |
SCHW
Charles Schwab
SCHW
|
+$36.1M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$35.6M |
| 4 |
Danaher
DHR
|
+$30.5M |
| 5 |
uniQure
QURE
|
+$28.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$93.5M |
| 2 |
Mercado Libre
MELI
|
+$86M |
| 3 |
Microsoft
MSFT
|
+$62.9M |
| 4 |
Apple
AAPL
|
+$55.6M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$48.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.59% |
| 2 | Healthcare | 13.39% |
| 3 | Consumer Discretionary | 11.41% |
| 4 | Communication Services | 11.25% |
| 5 | Financials | 10.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
Atmos Energy
ATO
$29.7B
| $36.1M | 0.06% |
215,066
+13,428
| +7% | +$2.32M |
|
277
Encompass Health
EHC
$11.3B
| $35.9M | 0.06% |
337,839
-13,992
| -4% | -$1.62M |
|
278
Chipotle Mexican Grill
CMG
$43.9B
| $35.7M | 0.06% |
963,696
-12,389
| -1% | -$448K |
|
279
eBay
EBAY
$51.2B
| $35.4M | 0.05% |
406,031
-25,823
| -6% | -$2.24M |
|
280
Equity Residential
EQR
$25.8B
| $35.2M | 0.05% |
558,999
-9,409
| -2% | -$577K |
|
281
DexCom
DXCM
$29B
| $35.2M | 0.05% |
530,363
+43,990
| +9% | +$2.84M |
|
282
Telefônica Brasil
VIV
$20.4B
| $35M | 0.05% |
2,949,455
+37,899
| +1% | +$470K |
|
283
Oculis Holding
OCS
$655M
| $34.9M | 0.05% |
1,746,946
+493,827
| +39% | +$9.88M |
|
284
LPL Financial
LPLA
$27B
| $34.8M | 0.05% |
97,431
+4,737
| +5% | +$1.68M |
|
285
Corteva
CTVA
$60.5B
| $34.7M | 0.05% |
518,415
-6,629
| -1% | -$429K |
|
|
SION
286
Sionna Therapeutics
SION
$2.02B
| $34.6M | 0.05% |
839,960
-110,587
| -12% | -$4.19M |
|
287
First Solar
FSLR
$21.4B
| $34.4M | 0.05% |
131,529
-1,876
| -1% | -$473K |
|
288
Monolithic Power Systems
MPWR
$61.4B
| $34.2M | 0.05% |
37,703
-228
| -0.6% | -$219K |
|
289
Cloudflare
NET
$96B
| $34.1M | 0.05% |
173,037
-1,464
| -0.8% | -$310K |
|
290
Veralto
VLTO
$24.1B
| $34M | 0.05% |
340,512
-15,999
| -4% | -$1.62M |
|
291
Molina Healthcare
MOH
$10.4B
| $33.9M | 0.05% |
195,064
+59,498
| +44% | +$9.78M |
|
292
Ultragenyx Pharmaceutical
RARE
$2.46B
| $33.8M | 0.05% |
1,469,951
+496,295
| +51% | +$16.3M |
|
293
Xenon Pharmaceuticals
XENE
$6.1B
| $33.6M | 0.05% |
750,291
+171,146
| +30% | +$7.19M |
|
294
Denali Therapeutics
DNLI
$3.79B
| $33.6M | 0.05% |
2,032,967
+919,381
| +83% | +$15.5M |
|
295
Snowflake
SNOW
$98.1B
| $33.3M | 0.05% |
151,986
-1,670
| -1% | -$408K |
|
|
PPL
296
PPL Corp
PPL
$26.9B
| $33.2M | 0.05% |
949,231
-48,261
| -5% | -$1.74M |
|
297
KKR & Co
KKR
$89.1B
| $33.1M | 0.05% |
259,657
-3,937
| -1% | -$490K |
|
|
AXON
298
Axon Enterprise
AXON
$42.8B
| $32.9M | 0.05% |
57,852
-34,426
| -37% | -$21.4M |
|
299
Rivian
RIVN
$23.6B
| $32.5M | 0.05% |
1,649,661
-39,039
| -2% | -$620K |
|
300
Rio Tinto
RIO
$152B
| $32.3M | 0.05% |
403,747
+100,247
| +33% | +$7.22M |
|
Similar funds
Aberdeen Group's Q4 2025 Portfolio in Review
As of Q4 2025, Aberdeen Group held 995 positions worth $64.6B, up 2.2% from $63.2B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Aberdeen Group's Q4 2025 filing shows 43 new, 362 increased, 491 reduced and 59 closed positions. Its largest new stake was Praxis Precision Medicines: 134,992 shares worth $39.8M. The largest sale was Eli Lilly, an estimated $93.5M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, down from 33% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Aberdeen Group's largest Q4 2025 buy was Praxis Precision Medicines: 134,992 shares worth $39.8M.
- Aberdeen Group added most to Nu Holdings in Q4 2025, an estimated $36.3M increase.
- Aberdeen Group's biggest Q4 2025 reduction was Eli Lilly, cutting an estimated $93.5M.
- Aberdeen Group fully exited BioMarin Pharmaceuticals in Q4 2025, selling an estimated $48.9M.
- Aberdeen Group's ten largest holdings make up 38% of its $64.6B portfolio in Q4 2025.
- Aberdeen Group opened 43 new positions and closed 59 in Q4 2025.
- Aberdeen Group's portfolio value rose 2.2% quarter-over-quarter to $64.6B.
Based on Aberdeen Group's 13F filing for Q4 2025, filed 16 Jan 2026.